• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BTG wins CE Mark for DC Bead Lumi radiopaque drug-eluting bead

March 7, 2017 By Sarah Faulkner

BTG wins CE Mark for DC Bead Lumi radiopaque drug-eluting beadBTG (LON:BTG) said today that it won CE Mark clearance in the European Union for its DC Bead Lumi radiopaque drug-eluting bead. The bead is designed to be loaded with doxorubicin or irinotecan to locally treat tumors in patients with hepatocellular carcinoma and malignant colorectal cancer metastasised to the liver.

The company’s DC Bead Lumi also features real-time visible confirmation of the bead’s location, which the company claims will enhance control in transarterial chemoembolisation procedures.

The bead, which can be seen during and after embolisation, enables doctors to individualize a patient’s treatment and evaluate the completeness of tumor treatment, according to BTG.

“The ability to see bead location during TACE procedures is a key step in enhancing the quality and potentially minimising complications of the procedure, and can help improve treatment outcomes compared to current techniques,” Dr. Tobias Jakobs, from the Hospital of the Order of St. John of God in Germany, said in prepared remarks. “More importantly, the lasting radiopacity of DC Bead Lumi means I can show patients that treatment has been placed exactly where it’s needed.”

BTG also incorporated long-term radiopacity into the design of the drug-eluting bead, which makes the bead visible in follow-up scans to help identify areas of treatment and undertreatment.

“The Class III CE Mark approval for DC Bead Lumi is a real milestone and reinforces BTG’s leadership in embolisation technology, following on closely from our recent Class III CE Mark approval for DC Bead and DC BeadM1,” BTG head of interventional oncology Duncan Kennedy added. “DC Bead Lumi, the first ever radiopaque DEB, brings a new level of control enabling doctors to see rather than assume the location of the beads, providing the ability to adjust and optimise the embolisation procedure as they go. DC Bead Lumi is the next step in our ongoing commitment to transform cancer care with smarter solutions.”

Filed Under: Drug-Device Combinations, Featured, Oncology, Regulatory/Compliance, Wall Street Beat Tagged With: BTG

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS